EP3681861A4 - Cxcr-2-inhibitoren zur behandlung von störungen - Google Patents

Cxcr-2-inhibitoren zur behandlung von störungen Download PDF

Info

Publication number
EP3681861A4
EP3681861A4 EP18856459.5A EP18856459A EP3681861A4 EP 3681861 A4 EP3681861 A4 EP 3681861A4 EP 18856459 A EP18856459 A EP 18856459A EP 3681861 A4 EP3681861 A4 EP 3681861A4
Authority
EP
European Patent Office
Prior art keywords
cxcr
inhibitors
treating disorders
disorders
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18856459.5A
Other languages
English (en)
French (fr)
Other versions
EP3681861A1 (de
Inventor
Payal Nanavati
Johan Hoegstedt
Jesse Hall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ardea Biociences Inc
Original Assignee
Ardea Biociences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/702,693 external-priority patent/US20180221312A1/en
Application filed by Ardea Biociences Inc filed Critical Ardea Biociences Inc
Publication of EP3681861A1 publication Critical patent/EP3681861A1/de
Publication of EP3681861A4 publication Critical patent/EP3681861A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP18856459.5A 2017-09-12 2018-09-12 Cxcr-2-inhibitoren zur behandlung von störungen Pending EP3681861A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/702,693 US20180221312A1 (en) 2016-03-11 2017-09-12 Cxcr-2 inhibitors for treating disorders
PCT/US2018/050656 WO2019055509A1 (en) 2017-09-12 2018-09-12 INHIBITORS OF CXCR-2 FOR THE TREATMENT OF DISORDERS

Publications (2)

Publication Number Publication Date
EP3681861A1 EP3681861A1 (de) 2020-07-22
EP3681861A4 true EP3681861A4 (de) 2021-06-09

Family

ID=65723077

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18856459.5A Pending EP3681861A4 (de) 2017-09-12 2018-09-12 Cxcr-2-inhibitoren zur behandlung von störungen

Country Status (11)

Country Link
EP (1) EP3681861A4 (de)
JP (1) JP2020533332A (de)
CN (1) CN111356675A (de)
AR (1) AR112801A1 (de)
AU (1) AU2018334152A1 (de)
BR (1) BR112020004697A2 (de)
CA (1) CA3075305A1 (de)
CO (1) CO2020003061A2 (de)
MX (2) MX2020002754A (de)
TW (1) TW201919599A (de)
WO (1) WO2019055509A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6883917B2 (ja) 2016-03-11 2021-06-09 アルデア バイオサイエンシーズ インク． 結晶性関節障害を処置するためのｃｘｃｒ−２阻害剤
US20220404373A1 (en) * 2019-09-25 2022-12-22 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and treating uveitis
WO2021089715A1 (en) * 2019-11-06 2021-05-14 Murray And Poole Enterprises, Ltd. Use of colchicine in the treatment and prevention of lung cancer
EP4058456A1 (de) * 2019-11-13 2022-09-21 RAPT Therapeutics, Inc. Kristalline formen des c-c-chemokinrezeptor-typ-4-agonisten und deren verwendungen
IL298748A (en) * 2020-06-05 2023-02-01 Aristea Therapeutics Inc Use of a combination of colchicine and a CXCR-2 inhibitor for the treatment or prevention of hereditary Mediterranean fever (FMF) and its outbreaks
TWI774059B (zh) * 2020-09-14 2022-08-11 國立陽明大學 Ｃｘｃｌ５中和抗體用於製備預防或治療周邊動脈阻塞疾病的藥物的用途
TW202227081A (zh) * 2020-09-15 2022-07-16 美商雅力思提雅治療公司 用於治療掌蹠膿疱症之組合物及方法
JP2023543248A (ja) * 2020-09-24 2023-10-13 ▲広▼州▲輯▼因医▲療▼科技有限公司 ヒト造血幹細胞移植効率を向上させるための化合物の使用
CN115385865B (zh) * 2022-06-29 2023-06-16 深圳大学 一种具有cxcr2抑制活性的小分子抑制剂及其制备方法与应用
CN117503740A (zh) * 2023-11-09 2024-02-06 复旦大学 一种bach1抑制剂及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140228339A1 (en) * 2011-07-12 2014-08-14 Astrazeneca Ab Novel Compound
WO2017156270A1 (en) * 2016-03-11 2017-09-14 Ardea Biosciences, Inc. Cxcr-2 inhibitors for treating crystal arthropathy disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06008599A (es) * 2004-01-30 2006-08-28 Schering Corp Polimorfos cristalinos de un ligando receptor de cxc-quimiocina.
US8298533B2 (en) * 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140228339A1 (en) * 2011-07-12 2014-08-14 Astrazeneca Ab Novel Compound
WO2017156270A1 (en) * 2016-03-11 2017-09-14 Ardea Biosciences, Inc. Cxcr-2 inhibitors for treating crystal arthropathy disorders
EP3426253A1 (de) * 2016-03-11 2019-01-16 Ardea Biosciences, Inc. Cxcr-2-inhibitoren zur behandlung von kristallarthropathien

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2019055509A1 *

Also Published As

Publication number Publication date
EP3681861A1 (de) 2020-07-22
CO2020003061A2 (es) 2020-06-19
AU2018334152A1 (en) 2020-04-23
AR112801A1 (es) 2019-12-11
BR112020004697A2 (pt) 2020-10-27
CN111356675A (zh) 2020-06-30
JP2020533332A (ja) 2020-11-19
TW201919599A (zh) 2019-06-01
CA3075305A1 (en) 2019-03-21
WO2019055509A1 (en) 2019-03-21
MX2022014868A (es) 2022-12-15
MX2020002754A (es) 2020-07-20

Similar Documents

Publication Publication Date Title
EP3681861A4 (de) Cxcr-2-inhibitoren zur behandlung von störungen
EP3349760A4 (de) Zusammensetzungen und verfahren zur behandlung neurologischer störungen
AU2016282790B9 (en) VMAT2 inhibitors for treating neurological diseases or disorders
EP3307713A4 (de) Ezh2-hemmer zur behandlung von lymphomen
EP3256218A4 (de) Kdm1a-hemmer zur behandlung von krankheiten
EP3261640A4 (de) 5ht-agonisten zur behandlung von erkrankungen
EP3380121A4 (de) Verfahren zur behandlung von augenerkrankungen
EP3500289A4 (de) Verfahren zur behandlung von tracheobronchomalazie
EP3157527A4 (de) Ezh2-hemmer zur behandlung von lymphomen
EP3331550A4 (de) Verfahren zur behandlung von myeloproliferativen erkrankungen
EP3329018A4 (de) Verfahren zur behandlung von hepcidin-vermittelten krankheiten
EP3526328A4 (de) Kombinationstherapie für c3-inhibition
EP3283655A4 (de) Verfahren zur behandlung von myeloproliferativen erkrankungen
EP3307068A4 (de) Mct4-inhibitoren zu behandlung von erkrankungen
EP3189036A4 (de) Zusammensetzungen und verfahren zur behandlung von proliferativen erkrankungen
EP3316887A4 (de) Gls1-hemmer zu behandlung von erkrankungen
EP3697764A4 (de) Glutaminase-hemmertherapie
EP3426253A4 (de) Cxcr-2-inhibitoren zur behandlung von kristallarthropathien
EP3119911A4 (de) Verfahren zur behandlung von neurologischen erkrankungen
EP3706753A4 (de) Inhibitor des adenosinwegs zur krebsbehandlung
EP3471830A4 (de) Ezh2-hemmer zu behandlung von krebs
EP3164394A4 (de) Gls1-hemmer zu behandlung von erkrankungen
EP3703707A4 (de) Verfahren zur behandlung von säure-basen-störungen
EP3677265A4 (de) Zusammensetzung zur vorbeugung oder behandlung von schlafstörungen
EP3600301A4 (de) Kdm4-inhibitoren

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200320

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40032874

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20210511

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 205/00 20060101AFI20210504BHEP

Ipc: A61K 31/167 20060101ALI20210504BHEP

Ipc: A61K 31/341 20060101ALI20210504BHEP

Ipc: A61K 45/06 20060101ALI20210504BHEP

Ipc: A61P 29/00 20060101ALI20210504BHEP

Ipc: C07F 9/568 20060101ALI20210504BHEP

Ipc: A61K 31/165 20060101ALI20210504BHEP

Ipc: A61K 31/506 20060101ALI20210504BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220803